Pattern of breast cancer susceptibility gene 1 expression is a potential prognostic biomarker in resectable pancreatic ductal adenocarcinoma

Pancreas

Volumn 42, Issue 6, 2013, Pages 977-982

  Wang, Tong ^a   Wentz, Sabrina C ^a   Ausborn, Natalie L ^a   Washington, M Kay ^a   Merchant, Nipun ^a   Zhao, Zhiguo ^b   Shyr, Yu ^b   Chakravarthy, A Bapsi ^a   Xia, Fen ^c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

BRCA1 expression; BRCA1 localization

Indexed keywords

BIOLOGICAL MARKER; BRCA1 PROTEIN; MESSENGER RNA;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL NUCLEUS; CELLULAR DISTRIBUTION; CYTOSOL; FEMALE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; TISSUE MICROARRAY; TUMOR GROWTH;

ADENOCARCINOMA; AGED; BRCA1 PROTEIN; CARCINOMA, PANCREATIC DUCTAL; CELL NUCLEUS; CYTOPLASM; DISEASE-FREE SURVIVAL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICROSCOPY, FLUORESCENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84880693701     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e318287885c     Document Type: Article

References (33)

1. Siegel R, Naishadham D, Jermal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. Yeo CJ, Abrams RA, Grochow LB, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg. 1997;225:621-633.
3. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567-579.
4. Cameron JL, Pitt HA, Yeo CJ, et al. One hundred and forty-five consecutive pancreaticoduodenectomies without mortality. Ann Surg. 1993;217:430-438.
5. Balcom JH 4th, Rattner DW, Warshaw AL, et al. Ten-year experience with 733 pancreatic resections: changing indications, older patients, and decreasing length of hospitalization. Arch Surg. 2001;136:391-398.
6. Birkmeyer JD, Finlayson SR, Tosteson AN, et al. Effect of hospital volume on in-hospital mortality with pancreaticoduodenectomy. Surgery. 1999;125:250-256.
7. Hsu CC, Herman JM, Corsini MM, et al. Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol. 2010;17:981-990.
8. Corsini MM, Miller RC, Haddock MG, et al. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005). J Clin Oncol. 2008;26:3511-3516.
9. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230:776-782.
10. Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001;358:1576-1585.
11. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200-1210.
12. Wang B, Matsuoka S, Ballif BA, et al. Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. Science. 2007;316:1194-1198.
13. Kim H, Chen J, Yu X. Ubiquitin-binding protein RAP80 mediates BRCA1-dependent DNA damage response. Science. 2007;316:1202-1205.
14. Kim H, Huang J, Chen J. CCDC98 is a BRCA1-BRCT domain-binding protein involved in. the DNA damage response. Nature Struct Mol Biol. 2007;14:710-715.
15. Johnson RD, Jasin M. Sister chromatid gene conversion is a prominent double-strand break repair pathway in mammalian cells. EMBO J. 2000;19:3398-3407.
16. Fabbro M, Schuechner S, Au WWY, et al. BARD1 regulates BRCA1 apoptotic function by a mechanism involving nuclear retention. Exp Cell Res. 2004;298:661-673.
17. Yang ES, Xia F. BRCA1 16 years later: DNA-damage induced BRCA1 shuttling. FEBS J. 2010;277:3079-3085.
18. Rosell R, Skrzypski M, Jassem E, et al. BRCA1: a novel prognostic factor in resected nonYsmall-cell lung cancer. PLoS ONE. 2007;2:e1129.
19. Banerjee S, Kaye S. PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond. Curr Oncol Rep. 2011;13:442-449.
20. Comen EA, Robson M. Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer. Cancer K. 2010;16:48-52.
21. Wei J, Costa C, Ding Y, et al. mRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancer. Brief communication. J Natl Cancer Inst. 2011;103: 1552-1556.
22. Thompson D, Easton DF, Breast Cancer Linkage Consortium. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst. 2002;94:1358-1365.
23. Edge SB, Byrd DR, Compton CC, et al, eds. AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010.
24. Washington K, Tang LH, Berlin J, et al. Protocol for the Examination of Specimens from Patients with Carcinoma of the Endocrine Pancreas. College of American Pathologists Cancer Protocols: Pancreas (exocrine); 2009.
25. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Statist Med. 2011;30:377-399.
26. Harrell FE. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York: Springer; 2001.
27. R Development Core Team. A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2011.
28. Rakha EA, El-Sheikh SE, Kandil MA, et al. Expression of BRCA1 protein in breast cancer and its prognostic significance. Hum Pathol. 2008;39:857-865.
29. Coene ED, Gadelha C, White N, et al. A novel role for BRCA1 in regulating breast cancer cell spreading and motility. J Cell Biol. 2011;192:497-512.
30. Fogelman DR, Wolff RA, Kopetz S, et al. Evidence for the efficacy of iniparib, a PARP-inhibitor, in BRCA2-associated pancreatic cancer. Anticancer Res. 2011;31:1417-1420.
31. Drew Y, Mulligan EA, Vong WT, et al. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst. 2011;103:334-346.
32. Zheng Z, Chen T, Li X, et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Eng J Med. 2007;356:800-808.
33. Su C, Zhou S, Zhang L, et al. ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced nonYsmall cell lung cancer. Med Oncol. 2011;28:1411-1417.